Top

Published in:

Open Access 01-12-2008 | Research

Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma

Authors: Eric Smith, Neville J De Young, Sandra J Pavey, Nicholas K Hayward, Derek J Nancarrow, David C Whiteman, B Mark Smithers, Andrew R Ruszkiewicz, Andrew D Clouston, David C Gotley, Peter G Devitt, Glyn G Jamieson, Paul A Drew

Published in: Molecular Cancer | Issue 1/2008

Abstract

Background

Barrett's esophagus (BE) is the metaplastic replacement of squamous with columnar epithelium in the esophagus, as a result of reflux. It is the major risk factor for the development of esophageal adenocarcinoma (EAC). Methylation of CpG dinucleotides of normally unmethylated genes is associated with silencing of their expression, and is common in EAC. This study was designed to determine at what stage, in the progression from BE to EAC, methylation of key genes occurs.

Results

We examined nine genes (APC, CDKN2A, ID4, MGMT, RBP1, RUNX3, SFRP1, TIMP3, and TMEFF2), frequently methylated in multiple cancer types, in a panel of squamous (19 biopsies from patients without BE or EAC, 16 from patients with BE, 21 from patients with EAC), BE (40 metaplastic, seven high grade dysplastic) and 37 EAC tissues. The methylation frequency, the percentage of samples that had any extent of methylation, for each of the nine genes in the EAC (95%, 59%, 76%, 57%, 70%, 73%, 95%, 74% and 83% respectively) was significantly higher than in any of the squamous groups. The methylation frequency for each of the nine genes in the metaplastic BE (95%, 28%, 78%, 48%, 58%, 48%, 93%, 88% and 75% respectively) was significantly higher than in the squamous samples except for CDKN2A and RBP1. The methylation frequency did not differ between BE and EAC samples, except for CDKN2A and RUNX3 which were significantly higher in EAC. The methylation extent was an estimate of both the number of methylated alleles and the density of methylation on these alleles. This was significantly greater in EAC than in metaplastic BE for all genes except APC, MGMT and TIMP3. There was no significant difference in methylation extent for any gene between high grade dysplastic BE and EAC.

Conclusion

We found significant methylation in metaplastic BE, which for seven of the nine genes studied did not differ in frequency from that found in EAC. This is also the first report of gene silencing by methylation of ID4 in BE or EAC. This study suggests that metaplastic BE is a highly abnormal tissue, more similar to cancer tissue than to normal epithelium.

Available only for authorised users

Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS: Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology. 2000, 119: 333-338. 10.1053/gast.2000.9302CrossRefPubMed

Murray L, Watson P, Johnston B, Sloan J, Mainie IM, Gavin A: Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ. 2003, 327: 534-535. 10.1136/bmj.327.7414.534PubMedCentralCrossRefPubMed

Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ: NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007, 4: e67- 10.1371/journal.pmed.0040067PubMedCentralCrossRefPubMed

Keswani RN, Noffsinger A, Waxman I, Bissonnette M: Clinical use of p53 in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1243-1249. 10.1158/1055-9965.EPI-06-0010CrossRefPubMed

Tannapfel A: Molecular findings in Barrett's epithelium. Dig Dis. 2004, 22: 126-133. 10.1159/000080311CrossRefPubMed

Peters CJ, Fitzgerald RC: Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2007, 25: 1253-1269.CrossRefPubMed

Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996, 93: 9821-9826. 10.1073/pnas.93.18.9821PubMedCentralCrossRefPubMed

Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28: E32- 10.1093/nar/28.8.e32PubMedCentralCrossRefPubMed

Paulson TG, Reid BJ: Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell. 2004, 6: 11-16. 10.1016/j.ccr.2004.06.021CrossRefPubMed

10.

Clement G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J: Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol. 2006, 208: 100-107. 10.1002/path.1884CrossRefPubMed

11.

Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, Burgart LJ, Ahlquist DA: Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer. 2005, 116: 584-591. 10.1002/ijc.21045CrossRefPubMed

12.

Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA, Laird PW: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001, 61: 3410-3418.PubMed

13.

Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E: Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene. 2005, 24: 4138-4148.CrossRefPubMed

14.

Coppe JP, Smith AP, Desprez PY: Id proteins in epithelial cells. Exp Cell Res. 2003, 285: 131-145. 10.1016/S0014-4827(03)00014-4CrossRefPubMed

15.

Norton JD: ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci. 2000, 113 (Pt 22): 3897-3905.PubMed

16.

Hagiwara K, Nagai H, Li Y, Ohashi H, Hotta T, Saito H: Frequent DNA methylation but not mutation of the ID4 gene in malignant lymphoma. J Clin Exp Hematop. 2007, 47: 15-18. 10.3960/jslrt.47.15CrossRefPubMed

17.

Chan AS, Tsui WY, Chen X, Chu KM, Chan TL, Chan AS, Li R, So S, Yuen ST, Leung SY: Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. Oncogene. 2003, 22: 6946-6953. 10.1038/sj.onc.1206799CrossRefPubMed

18.

Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DS: Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res. 2004, 10: 7475-7483. 10.1158/1078-0432.CCR-04-0689CrossRefPubMed

19.

Dahl C, Guldberg P: A ligation assay for multiplex analysis of CpG methylation using bisulfite-treated DNA. Nucleic Acids Res. 2007, 35: e144- 10.1093/nar/gkm984PubMedCentralCrossRefPubMed

20.

Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE, Hoon DS: Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene. 2005, 24: 4721-4727. 10.1038/sj.onc.1208538CrossRefPubMed

21.

Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, Xu Y, Olaru A, Berki AT, Li H: Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene. 2006, 25 (23): 3346-3356. 10.1038/sj.onc.1209357CrossRefPubMed

22.

Jenkins GJ, Doak SH, Parry JM, D'Souza FR, Griffiths AP, Baxter JN: Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg. 2002, 89: 824-837. 10.1046/j.1365-2168.2002.02107.xCrossRefPubMed

23.

Lin L, Wang Z, Prescott MS, van Dekken H, Thomas DG, Giordano TJ, Chang AC, Orringer MB, Gruber SB, Moran JV: Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma. Genes Chromosomes Cancer. 2006, 45: 319-331. 10.1002/gcc.20293CrossRefPubMed

24.

Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, Reid BJ: p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. 2001, 61: 8284-8289.PubMed

25.

Fahmy M, Skacel M, Gramlich TL, Brainard JA, Rice TW, Goldblum JR, Connor JT, Casey G, Legator MS, Tubbs RR, Falk GW: Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod Pathol. 2004.

26.

Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ: Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene. 1996, 13: 1867-1873.PubMed

27.

Walch AK, Zitzelsberger HF, Bruch J, Keller G, Angermeier D, Aubele MM, Mueller J, Stein H, Braselmann H, Siewert JR: Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol. 2000, 156: 555-566.PubMedCentralCrossRefPubMed

28.

Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, Reid BJ: Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet. 1999, 22: 106-109. 10.1038/8816PubMedCentralCrossRefPubMed

29.

Dolan K, Garde J, Walker SJ, Sutton R, Gosney J, Field JK: LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. Hum Pathol. 1999, 30: 1508-1514. 10.1016/S0046-8177(99)90175-2CrossRefPubMed

30.

Hardie LJ, Darnton SJ, Wallis YL, Chauhan A, Hainaut P, Wild CP, Casson AG: p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett. 2005, 217: 221-230. 10.1016/j.canlet.2004.06.025CrossRefPubMed

31.

Novotna K, Trkova M, Pazdro A, Smejkal M, Soukupova A, Kodetova D, Smejkal P, Sedlacek Z: TP53 gene mutations are rare in nondysplastic Barrett's esophagus. Dig Dis Sci. 2006, 51: 110-113. 10.1007/s10620-006-3093-3CrossRefPubMed

32.

Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T: Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol. 1993, 119: 441-449. 10.1007/BF01215923CrossRefPubMed

33.

Boonstra JJ, Velden van der AW, Beerens EC, van Marion R, Morita-Fujimura Y, Matsui Y, Nishihira T, Tselepis C, Hainaut P, Lowe AW: Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7. Cancer Res. 2007, 67: 7996-8001. 10.1158/0008-5472.CAN-07-2064CrossRefPubMed

34.

Smith E, Drew PA, Tian ZQ, De Young NJ, Liu JF, Mayne GC, Ruszkiewicz AR, Watson DI, Jamieson GG: Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer. 2005, 4: 42- 10.1186/1476-4598-4-42PubMedCentralCrossRefPubMed

35.

Smith E, De Young NJ, Tian ZQ, Caruso M, Ruszkiewicz AR, Liu JF, Jamieson GG, Drew PA: Methylation of TIMP3 in esophageal squamous cell carcinoma. World J Gastroenterol. 2008, 14: 203-210. 10.3748/wjg.14.203PubMedCentralCrossRefPubMed

Title: Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma
Authors: Eric Smith
Neville J De Young
Sandra J Pavey
Nicholas K Hayward
Derek J Nancarrow
David C Whiteman
B Mark Smithers
Andrew R Ruszkiewicz
Andrew D Clouston
David C Gotley
Peter G Devitt
Glyn G Jamieson
Paul A Drew
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2008
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-7-75

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties?

ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells

The prince and the pauper. A tale of anticancer targeted agents

Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity

Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival

A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer